Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience — Philadelphia, Pennsylvania

Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience is a clinical research site located in Philadelphia, Pennsylvania, United States 19107.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience has participated in 1 clinical trials.

Therapeutic areas: Aneurysmal Subarachnoid Hemorrhage.

Sponsors: Idorsia Pharmaceuticals Ltd..

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience?

Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience conducted?

Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience has 1 clinical trials on record. Their work covers Aneurysmal Subarachnoid Hemorrhage.

Is Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience accredited by Crixeo Health?

Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Thomas Jefferson University School of Medicine-Jefferson Hospital for Neuroscience?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.